CINCINNATI, May 6, 2011 /PRNewswire/ — Kendle (Nasdaq:
KNDL), a leading, global full-service clinical research
organization, today announced the Company is postponing its Annual
Meeting of Shareholders due to its merger agreement with INC
Research, LLC. The annual meeting had been scheduled for May
19, 2011, in Cincinnati, Ohio. Kendle announced May 4, 2011,
that it has signed a merger agreement with INC Research. The
merger transaction requires the approval of Kendle’s
shareholders.
The annual meeting was postponed to provide shareholders
adequate information and time to review the proposed merger.
At a later date, Kendle’s Board of Directors will establish a
new record date and meeting date for the annual meeting and the
Company will send a revised annual meeting notice and proxy
statement to shareholders.
Kendle believes it is appropriate to avoid the unnecessary cost
of holding both an annual meeting to address the five proposals
included in the Proxy Statement sent April 15, 2011, and another
special shareholders’ meeting to approve the merger.
About Kendle
Kendle International Inc. (Nasdaq:
KNDL) is a leading global clinical research organization
providing the full range of early- to late-stage clinical
development services for the world’s biopharmaceutical industry.
Our focus is on innovative solutions that reduce cycle times
for our customers and accelerate the delivery of life-enhancing
products to market for the benefit of patients worldwide. As
one of the world’s largest global providers of Phase I-IV services,
we offer experience spanning more than 100 countries, along with
industry-leading patient access and retention capabilities and
broad therapeutic expertise, to meet our customers’ clinical
development challenges.
‘/>”/>
